Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tharimmune, Inc. - Common Stock (NQ: THAR ) 2.450 -0.010 (-0.41%) Streaming Delayed Price Updated: 3:54 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 19,857 Open 2.470 Bid (Size) 2.310 (11) Ask (Size) 2.800 (4) Prev. Close 2.460 Today's Range 2.342 - 2.578 52wk Range 2.250 - 142.50 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab September 16, 2024 Via ACCESSWIRE THAR Stock Earnings: Tharimmune Reported Results for Q2 2024 August 12, 2024 Tharimmune just reported results for the second quarter of 2024. Via InvestorPlace Performance YTD -67.65% -67.65% 1 Month -16.95% -16.95% 3 Month -24.15% -24.15% 6 Month -62.03% -62.03% 1 Year -96.75% -96.75% More News Read More Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board July 22, 2024 Via ACCESSWIRE Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor July 17, 2024 Via ACCESSWIRE Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 July 16, 2024 Via ACCESSWIRE Why Tharimmune (THAR) Shares Are Moving May 22, 2024 Via Benzinga THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 May 09, 2024 Via InvestorPlace Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor July 10, 2024 Via ACCESSWIRE Tharimmune Announces $2.08 Million Private Placement June 20, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Pre-Market Session June 17, 2024 Via Benzinga Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis June 17, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Intraday Session June 10, 2024 Via Benzinga Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 10, 2024 Via Benzinga Why Tharimmune (THAR) Shares Are Getting Hammered June 10, 2024 Via Benzinga Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis June 10, 2024 Via ACCESSWIRE Tharimmune to Present at 2024 BIO International Convention May 29, 2024 Via ACCESSWIRE Why Is Verastem (VSTM) Stock Down 62% Today? May 24, 2024 Via InvestorPlace Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? May 24, 2024 Via InvestorPlace Why Is Tharimmune (THAR) Stock Moving Today? May 24, 2024 Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 24, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 22, 2024 Via Benzinga Tharimmune Announces 1-for-15 Reverse Stock Split May 22, 2024 Via ACCESSWIRE Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference May 16, 2024 Via Investor Brand Network Tharimmune To Participate in Two Upcoming Investor Conferences in May April 30, 2024 Via ACCESSWIRE Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) April 23, 2024 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
